Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
VANCOUVER, British Columbia, Feb. 10, 2021 -- InvestorsHub NewsWire -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or...
VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...
Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19 VANCOUVER, British Columbia, June 04, 2020...
Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard Gutman to Advisory Board VANCOUVER, British Columbia, Canada...
Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use VANCOUVER, British Columbia, Canada -- March 13, 2020...
Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus VANCOUVER, British Columbia, Canada -- March 6, 2020 -- InvestorsHub NewsWire -- Algernon...
Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD...
Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in a Recent Idiopathic Pulmonary Fibrosis Study by...
Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments...
#outlook a {padding:0;} body {width:100%; -webkit-text-size-adjust:100%; -ms-text-size-adjust:100%; margin:0; padding:0;} .ReadMsgBody {width:100%;} .ExternalClass...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.005 | -6.66666666667 | 0.075 | 0.075 | 0.06 | 62637 | 0.06831383 | CS |
| 4 | -0.005 | -6.66666666667 | 0.075 | 0.085 | 0.06 | 43778 | 0.07271723 | CS |
| 12 | -0.02 | -22.2222222222 | 0.09 | 0.1 | 0.06 | 30241 | 0.0765144 | CS |
| 26 | -0.06 | -46.1538461538 | 0.13 | 0.14 | 0.06 | 26237 | 0.09523409 | CS |
| 52 | -0.015 | -17.6470588235 | 0.085 | 0.165 | 0.06 | 30307 | 0.0979549 | CS |
| 156 | -1.18 | -94.4 | 1.25 | 2.975 | 0.05 | 17819 | 0.24659968 | CS |
| 260 | 0.0575 | 460 | 0.0125 | 2.975 | 0.01125 | 331764 | 0.07714682 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
